Ian Garbarine, MD (he/him/his)

General Surgery Resident
Ohio State University
Columbus, Ohio, United States

Presentation(s):

• P40. Receipt of adjuvant checkpoint inhibitor therapy for melanoma and risk of subsequent skin cancer

  Thursday, March 5, 2026
  2:18 PM - 2:25 PM MST

• P48. Duration of adjuvant immunotherapy in sentinel node positive melanoma: How important is completing a full year?

  Thursday, March 5, 2026
  3:14 PM - 3:21 PM MST

• BP4. Dasatinib reverses myeloid derived suppressor cell (MDSC) inhibition of T-cell proliferation in a triple negative breast cancer model

  Friday, March 6, 2026
  8:23 AM - 8:30 AM MST